U.S.-based Johnson & Johnson posted full-year 2022 net income of $17.941 billion (16.508 billion euros), down 14.1 percent from 2021.
Revenues, meanwhile, were $94,943 million (87,361 million euros), down 4.4 percent. Of this revenue, 55.5 percent came from the pharmaceutical division, 28.8 percent from medical technologies and the remaining 15.7 percent from consumer health products such as cosmetics.
Profits for the fourth quarter were 3,520 million dollars (3,239 million euros), up 25.7 percent year-on-year.
Quarterly revenues were 4.4 percent higher than in 2021, at 35.251 billion dollars (32.436 billion euros).
«The 2022 results show the strength and stability of our three market segments despite macroeconomic challenges,» said Joaquín Duato, CEO of Johnson & Johnson.
Source: (EUROPA PRESS)
